       Document 0766
 DOCN  M9590766
 TI    [Acute pancreatitis due to antimonials in patients with visceral
       leishmaniasis and HIV infection]
 DT    9509
 AU    Cortes E; Ribera E; Cucurull E; de Otero J; Ocana I; Pahissa A; Servicio
       de Medicina Interna, Hospital General Universitario Vall; d'Hebron,
       Universidad Autonoma, Barcelona.
 SO    Med Clin (Barc). 1995 Apr 22;104(15):578-80. Unique Identifier :
       AIDSLINE MED/95287674
 AB    Acute pancreatitis is an adverse effect of the treatment with antimonial
       drugs which is infrequently described in patients with HIV infection and
       visceral leishmaniasis (VL). Twenty-two percent of the patients having
       this treatment had acute pancreatitis (7 cases) in the authors' center.
       In all the cases, severe immunosuppression was present with pancreatitis
       appearing following the administration of 3,400 to 15,300 mg of
       stibogluconate. The pancreatitis was slight in the 7 cases with no
       complications of note and with no symptoms observed in three cases. The
       maximum values of amylasemia ranged from 976 to 2,568 U/l, from 1,055 to
       5,860 U/l for lipasemia, and from 1,970 to 25,520 U/l for trypsinemia.
       These values returned to normal from 15 days to 2 months after
       suppression of the drug. Stibogluconate was readministered in three
       patients due to VL recurrence with a further acute pancreatitis being
       observed. The authors conclude that acute pancreatitis is a relatively
       infrequent complication of antimonial treatment for VL in patients with
       HIV infection and believe that a maximum dose of 850 mg/day should not
       be surpassed.
 DE    Acute Disease  Adult  Antimony Sodium Gluconate/ADMINISTRATION &
       DOSAGE/*ADVERSE  EFFECTS  Antiprotozoal Agents/ADMINISTRATION &
       DOSAGE/*ADVERSE EFFECTS  AIDS-Related Opportunistic
       Infections/*COMPLICATIONS/DRUG THERAPY  English Abstract  Enzyme Tests
       Female  Human  *HIV-1  Leishmaniasis, Visceral/*COMPLICATIONS/DRUG
       THERAPY  Male  Meglumine/ADMINISTRATION & DOSAGE/*ADVERSE EFFECTS
       Organometallic Compounds/ADMINISTRATION & DOSAGE/*ADVERSE EFFECTS
       Pancreatitis/*CHEMICALLY INDUCED/DIAGNOSIS  Recurrence  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

